⌘K
Loading ticker…
As of 2026-09-10, Valion Bio, Inc. Common Stock (VBIO) has a 3-month relative strength percentile of 1 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 15.8 (Defensive). Sector: Healthcare, ranked 3 of 11. Average daily range 24.9%, relative volume 0.07×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Attention is elevated versus its own recent norm without the relative strength to match — the loud-but-lagging pattern. Worth a skeptical eye; not a short signal.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Not enough history to compute monthly seasonality for VBIO.